Hans J. Hammers
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 0.2%
- Molecular Biology top 2%
- Cancer Research top 0.5%
- Immunology top 2%
- Co-authors
- Brian I. RiniРоберто ПилиDavid F. McDermottElizabeth R. PlimackSaby GeorgeRobert J. MotzerMichael A. CarducciIan M. Waxman
- Topics
- Renal cell carcinoma treatment (157 papers)Cancer Immunotherapy and Biomarkers (86 papers)Cancer Genomics and Diagnostics (57 papers)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Hans J. Hammers
201 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 4.4k
- Pulmonary and Respiratory Medicine 4.1k
- Molecular Biology 3.0k
- Cancer Research 1.9k
- Immunology 1.2k
Countries citing papers authored by Hans J. Hammers
This map shows the geographic impact of Hans J. Hammers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Hammers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Hammers more than expected).
Fields of papers citing papers by Hans J. Hammers
This network shows the impact of papers produced by Hans J. Hammers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Hammers. The network helps show where Hans J. Hammers may publish in the future.
Co-authorship network of co-authors of Hans J. Hammers
This figure shows the co-authorship network connecting the top 25 collaborators of Hans J. Hammers. A scholar is included among the top collaborators of Hans J. Hammers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans J. Hammers. Hans J. Hammers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 2 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | 6 | |
| 6 | 2 | |
| 7 | 19 | |
| 8 | 2 | |
| 9 | 0 | |
| 10 | 16 | |
| 11 | 18 | |
| 12 | 25 | |
| 13 | 24 | |
| 14 | 3 | |
| 15 | 15 | |
| 16 | Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Studybreakdown → | 348 |
| 17 | 76 | |
| 18 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trialbreakdown → | 865 |
| 19 | 89 | |
| 20 | Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model | 1 |
About Hans J. Hammers
Hans J. Hammers is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 216 papers that have together received 8.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (157 papers), Cancer Immunotherapy and Biomarkers (86 papers) and Cancer Genomics and Diagnostics (57 papers). The work is most often cited by research in Oncology (4.4k citations), Pulmonary and Respiratory Medicine (4.1k citations) and Cancer Research (1.9k citations). Hans J. Hammers has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Brian I. Rini, Роберто Пили, David F. McDermott, Elizabeth R. Plimack, Saby George, Robert J. Motzer, Michael A. Carducci, Ian M. Waxman, Martin H. Voss and Asim Amin. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.